Document is current
Any future updates will be listed below
-
Authors
Helden, Sean R. Van
Coyne, Ashlan J. Kunz
Alosaimy, Sara
Molina, Kyle C.
Kang-Birken, S. Lena
Andrade, Justin
King, Madeline A.
Claeys, Kimberly C.
Hobbs, Athena L. V.
Perkins III, Nicholson B.
Agee, Jazmin
DeKerlegand, Alaina
Biagi, Mark
Veve, Michael P.
Tart, Serina
Gore, Tristan
Jones, Bruce M.
Pullinger, Benjamin M.
Schrack, Melanie Rae
Cosimi, Reese
Herbin, Shelbye R.
Judd, Chloe
Musawa, Mohammed Al
Rybak, Michael J.
-
Funding
Funding for this research was provided by:
Innoviva Specialty Therapeutics, Inc.
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 15 October 2025
First Online: 29 December 2025
Declarations
:
: This retrospective study was conducted using de-identified data and did not involve direct patient contact. As such, informed consent was waived by the Institutional Review Board. This study was reviewed and approved by the institutional review boards at Wayne State University (052019MP2X, protocol number 1905002252) and at each participating site and was conducted in accordance with the Declaration of Helsinki.
: MJR has received grant support/consulted or has participated on a speaker bureau for AbbVie, Innoviva, Melinta, Merck, and Shionogi. BMJ has consulted for or participated on a speaker bureau for Innovivia, AbbVie, Paratek, and Ferring. KCM has received grant support/consulted for Melintia, Merck, and Shionogi. All other authors declare no conflicts of interest.
